Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Selective bladder denervation shows potential for treating refractory OAB in women

12 Oct 2018

Selective bladder denervation provides a minimally invasive treatment option for female patients with refractory overactive bladder (OAB), with data from two prospective feasibility studies showing that the intervention improves symptoms over 6 months of follow-up.

The total population comprised 35 women (mean age 66 years) with refractory OAB and urgency urinary incontinence (UUI) who received selective bladder denervation of the subtrigonal region containing afferent sensory nerves. Patients were followed for 6 months and evaluated for OAB symptoms, health-related quality of life measures and adverse events.

All selective bladder denervation procedures were successfully completed, and symptom improvements based on 3-day bladder diaries were seen over the follow-up period. Specifically, UUI improved by 59 percent from baseline (p<0.001), urinary incontinence by 59 percent (p<0.001), urgency by 39 percent (p<0.001), urinary frequency by 9 percent (p=0.01), and total urgency and frequency score by 27 percent (p<0.001). The majority of these treatment benefits were observed in as early as the first month following treatment.

The rate of clinical success, defined as ≥50-percent reduction in UUI, was 70 percent. Treatment benefit was reported in 75 percent of patients, and the dry/cure rate was 27 percent.

Additionally, statistically significant increases in health-related quality of life were observed over 6 months, as reflected on Symptom Bother and Health-related Quality of Life scales on the OAB questionnaire, as well as on all domains of King’s Health Questionnaire except general health perception.

In terms of safety, device- or procedure-related adverse events occurred in six patients (17 percent).

A minimally invasive selective bladder denervation device includes a disposable transurethral instrument that accepts a rigid endoscope for visualization and has a lumen to facilitate addition and removal of fluids in the bladder. At the end of the lumen is a suction paddle that works to stabilize of the tissue and deliver the radiofrequency electrodes. [Neurourol Urodyn 2018;37:2097-2105]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.